AMBAR

Therapeutic plasma exchange

AMBAR is an innovative clinical trial aimed at slowing down the progression of Alzheimer’s disease through periodic therapeutic plasma exchange.

AMBAR targets a multimodal approach to the management of the disease based on the hypothesis that most of the amyloid-beta protein is bound to albumin and circulates in plasma. Extracting this plasma may flush amyloid-beta peptide from the brain into the plasma, thus potentially limiting the disease’s impact on the patient’s cognitive functions. Additionally, albumin has binding capacity and antioxidant properties, and both albumin and immunoglobulin display immunomodulatory and anti-inflammatory properties.

Based on this hypothesis, the build-up of beta-amyloid could be reduced before it can cause neuronal damage, thus potentially limiting the impact of Alzheimer’s disease on cognition.

LEARN MORE: Grifols


Mitophagy

Mitophagy in cellular homeostasis

Pathogenic protein species implicated in neurodegenerative diseases (e.g., alpha synuclein, beta amyloid, tau, and TDP43) can associate with mitochondria and drive mitochondrial dysfunction.

Mitophagy, the process by which cells clear their damaged mitochondria, plays an important protective role in these circumstances: not only is the normal, healthy mitochondrial pool restored, but the proteotoxic species are cleared along with the bad mitochondria.

Mitokinin’s scientists have shown that by potentiating the PINK1 pathway in times of proteotoxic stress, neuron health can be restored and disease-driving pathologies reduced or eliminated.

LEARN MORE: Mitokinin


Targeting misfolded proteins

Misfolded proteins

Proclara takes a novel approach to treating protein misfolding diseases, based on the fact that many toxic aggregates of misfolded proteins share a common characteristic – the amyloid protein fold – that represents a unique target for drug development.

Proclara scientists have developed a novel proprietary technology known as GAIM, or General Amyloid Interaction Motif, that simultaneously targets multiple misfolded proteins implicated in both neurodegenerative and progressive peripheral diseases, potentially creating a more robust response that could be suitable for patients at all stages of disease.

LEARN MORE: Proclara Biosciences